Addendum: Statement on nutritional supplements and piracetam for children with Down syndrome

Manisha Balwani, MD
Manisha Balwani
Affiliations
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai New York NY USA
American College of Medical Genetics and Genomics Bethesda MD USA
Search for articles by this author
The American College of Medical Genetics and Genomics (ACMG) Professional Practice and Guidelines Committee
*

The original statement was published in the ACMG newsletter in 1996.

This document was retired by the ACMG Board of Directors as of 27 April 2020 with the following addendum:

Based on the current literature,

^1.

Piracetam therapy does not enhance cognitive functioning in children with Down syndrome.

^,

^2.

Health supervision for children with Down syndrome.

the use of piracetam or other nutritional supplements in the health supervision for children with Down syndrome is not recommended.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

Accepted: May 14, 2020

Received: May 14, 2020

Elsevier user license |

How you can reuse Information Icon

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes